Efficacy and Safety Study of Two Fixed-dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate and Placebo (LAC-MD-27)
Efficacy and Safety Study of Two Fixed-Dose Combinations of Aclidinium Bromide With Formoterol Fumarate Compared With Aclidinium Bromide, Formoterol Fumarate, and Placebo All Administered Twice Daily (BID) to Patients With Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Type d'étude
Type d'étude
Inscription (Réel)
Inscription
Phase
Phase
- Phase 2
Contacts et emplacements
Lieux d'étude
-
-
Arizona
-
Glendale, Arizona, États-Unis, 85306
- Forest Investigative Site 0909
-
Pheonix, Arizona, États-Unis, 85006
- Forest Investigative Site 2050
-
-
California
-
Rancho Mirage, California, États-Unis, 92270
- Forest Investigative Site 2029
-
Stockton, California, États-Unis, 95207
- Forest Investigative Site 1084
-
-
Colorado
-
Wheat Ridge, Colorado, États-Unis, 80033
- Forest Investigative Site 2045
-
-
Florida
-
Clearwater, Florida, États-Unis, 33765
- Forest Investigative Site 1152
-
Tampa, Florida, États-Unis, 33603
- Forest Investigative Site 2053
-
Tampa, Florida, États-Unis, 33613
- Forest Investigative Site 2047
-
-
Massachusetts
-
N. Dartmouth, Massachusetts, États-Unis, 02747
- Forest Investigative Site 1431
-
-
New Jersey
-
Summit, New Jersey, États-Unis, 07901
- Forest Investigative Site 2084
-
-
New York
-
Elmira, New York, États-Unis, 14901
- Forest Investigative Site 1119
-
-
North Carolina
-
Elizabeth city, North Carolina, États-Unis, 27909
- Forest Investigative Site 2035
-
Raleigh, North Carolina, États-Unis, 27607
- Forest Investigative Site 1153
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45242
- Forest Investigative Site 2028
-
-
Oregon
-
Medford, Oregon, États-Unis, 97504
- Forest Investigative Site 2043
-
Portland, Oregon, États-Unis, 97213
- Forest Investigative Site 1106
-
-
Rhode Island
-
E. Providence, Rhode Island, États-Unis, 02914
- Forest Investigative Site 1089
-
-
South Carolina
-
Spartanburg, South Carolina, États-Unis, 29303
- Forest Investigative Site 1121
-
-
Texas
-
San Antonio, Texas, États-Unis, 78215
- Forest Investigative Site 1498
-
Waco, Texas, États-Unis, 76712
- Forest Investigative Site 1129
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Understand the study procedures and be willing to participate in the study as indicated by signing the ICF and HIPAA form
- Be male or female aged 40 to 80 years, inclusive
- Have a diagnosis of stable, moderate to severe COPD (stages II and III) as defined by guidelines of the Global Initiative for Chronic Obstructive Lung Disease (2008)
- Be a current or former cigarette smoker with a smoking history of at least 10 pack-years
- Have post-albuterol/salbutamol FEV1 values ≥ 30% and < 80% of the predicted value. FEV1 will be measured at the Screening Visit (Visit 1) between 10 and 15 minutes after inhalation of albuterol/salbutamol.
- Have post-albuterol/salbutamol FEV1/FVC values < 70% (ie, 100 × post- albuterol/salbutamol FEV1/FVC < 70%).
- If female, be at least 1 year postmenopausal or surgically sterile (defined as having a hysterectomy or tubal ligation). Women of childbearing potential must have a negative serum β-human chorionic gonadotropin pregnancy test at screening
- Be in good stable health (as judged by the Investigator) other than the COPD, based on medical history, physical examination, ECG, spirometry, and clinical laboratory data evaluations
- Have COPD symptoms and FEV1 values at the time of randomization that are stable compared with those at Screening (Visit 1), according to the Investigator's medical judgment
Exclusion Criteria:
- Have been hospitalized for an acute COPD exacerbation within 3 months before screening
- Have any respiratory tract infection (including the upper respiratory tract) or signs of a COPD exacerbation or respiratory infection in the 6 weeks before Screening (Visit 1).
- Have any clinically significant respiratory conditions other than COPD
- Have a history or presence of asthma verified from medical records
- Have used theophylline (including long-acting theophylline) within the previous 3 months before study entry
- Have Stage II hypertension, defined as systolic pressure of 160 and above, and diastolic pressure of 100 and above
- Chronic use of oxygen therapy ≥ 15 hours a day
- Have a history, current diagnosis, or presence of exercise-induced bronchospasm
- Have a body mass index ≥ 40 kg/m2
- Have participated in an pulmonary rehabilitation program within the previous 3 months
- Have clinically significant cardiovascular conditions
- Have uncontrolled infection resulting from human immunodeficiency virus and/or active hepatitis
- Have symptomatic prostatic hypertrophy and/or bladder neck obstruction.
- Have narrow-angle glaucoma
- Have a history of hypersensitivity reaction (including report of paradoxical bronchospasm) to inhaled anticholinergics (including aclidinium bromide), β2 adrenergic agonists, or any other inhaled medication or any component thereof
- Have a QTcB, as indicated in the centralized reading report, above 470 msec in the resting ECGs performed at Screening (Visit 1) and/or patients who are using medications that may prolong the QT interval
- Have clinically relevant abnormalities in the results of clinical laboratory tests, in ECG parameters other than QTc, in results of the physical examination,
- Have any concurrent medical condition that, in the judgment of the Investigator, might interfere with the conduct of the study, confound the interpretation of the study results, or endanger the patient's well-being
- Do not maintain regular day/night, waking/sleeping cycles (eg, patients with history of sleep apnea syndrome or any disease related with sleep disturbances such as restless legs syndrome or somnambulism)
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Quadruple
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Aclidinium 400 μg / Formoterol 12 μg
Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID)
|
Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.
|
|
Expérimental: Aclidinium 400 μg / formoterol 6 μg
Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID)
|
Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.
|
|
Expérimental: Aclidinium 400 μg
Aclidinium bromide 400 μg administered twice-daily (BID)
|
Aclidinium bromide 400 μg administered twice-daily (BID) for a 14 day period within four different treatment periods.
|
|
Comparateur actif: Formoterol 12 μg
Formoterol fumarate 12 μg twice-daily
|
Formoterol fumarate 12 μg twice-daily for a 14 day period within four different treatment periods.
|
|
Comparateur placebo: Placebo
Placebo twice-daily
|
Placebo twice-daily delivered by inhalation for a 14 day period within four different treatment periods.
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12)
Délai: 0 to 12 hours post-dose on Day 14
|
0 to 12 hours post-dose on Day 14
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Délai |
|---|---|
|
Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in One Second (FEV1)
Délai: Day 14
|
Day 14
|
|
Change From Baseline in Morning Peak Forced Expiratory Volume in One Second (FEV1)
Délai: Day 14
|
Day 14
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Publications et liens utiles
Liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement primaire
Achèvement de l'étude (Réel)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies des voies respiratoires
- Maladies pulmonaires
- Maladies pulmonaires obstructives
- Maladie pulmonaire obstructive chronique
- Effets physiologiques des médicaments
- Agents adrénergiques
- Agents neurotransmetteurs
- Mécanismes moléculaires de l'action pharmacologique
- Agents autonomes
- Agents du système nerveux périphérique
- Agonistes adrénergiques
- Agents bronchodilatateurs
- Agents anti-asthmatiques
- Agents du système respiratoire
- Agonistes des récepteurs bêta-2 adrénergiques
- Bêta-agonistes adrénergiques
- Fumarate de formotérol
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- LAC-MD-27
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .